Sodium-Glucose Cotransporter-2 Inhibitor (SGLT2) in Major Depressive Disorder (MDD)

NCT05757791 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

16

Enrollment

OTHER

Sponsor class

Conditions

Major Depressive Disorder

Interventions

DRUG: Empagliflozin

Sponsor

NYU Langone Health

Collaborators

[object Object]